DE60108094D1 - Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien - Google Patents

Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien

Info

Publication number
DE60108094D1
DE60108094D1 DE60108094T DE60108094T DE60108094D1 DE 60108094 D1 DE60108094 D1 DE 60108094D1 DE 60108094 T DE60108094 T DE 60108094T DE 60108094 T DE60108094 T DE 60108094T DE 60108094 D1 DE60108094 D1 DE 60108094D1
Authority
DE
Germany
Prior art keywords
agonists
joint
treatment
bone pathologies
retinoid antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60108094T
Other languages
English (en)
Other versions
DE60108094T2 (de
Inventor
Maurizio Pacifici
A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60108094D1 publication Critical patent/DE60108094D1/de
Application granted granted Critical
Publication of DE60108094T2 publication Critical patent/DE60108094T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE60108094T 2000-04-20 2001-04-19 Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien Expired - Fee Related DE60108094T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US552823 1990-07-16
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (2)

Publication Number Publication Date
DE60108094D1 true DE60108094D1 (de) 2005-02-03
DE60108094T2 DE60108094T2 (de) 2005-12-15

Family

ID=24206947

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60108094T Expired - Fee Related DE60108094T2 (de) 2000-04-20 2001-04-19 Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien

Country Status (9)

Country Link
US (1) US20030114482A1 (de)
EP (1) EP1274456B1 (de)
JP (1) JP2003531180A (de)
AT (1) ATE285794T1 (de)
AU (3) AU5548801A (de)
CA (1) CA2407021A1 (de)
DE (1) DE60108094T2 (de)
HK (1) HK1053053B (de)
WO (1) WO2001080894A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518719A (ja) * 2003-12-26 2007-07-12 アラーガン　インコーポレイテッド ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤
EP1959945B1 (de) * 2005-12-13 2014-12-03 McGill University Fenretinid zur korrektur des lipidungleichgewichts bei einer person
WO2009102789A2 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteroarthritis
HUE059024T2 (hu) 2010-09-01 2022-10-28 Univ Jefferson Összetétel és módszer az izom helyreállítására és regenerációjára
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
SG10201704687YA (en) 2012-11-08 2017-07-28 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
RS58045B1 (sr) 2013-05-22 2019-02-28 Univ Yamaguchi Inhibitor za retinohoroidalne poremećaje
IL263440B (en) 2016-06-08 2022-09-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
AU2017359673B2 (en) 2016-11-16 2021-10-21 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (MO)
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
JP3995716B2 (ja) * 1996-03-18 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合環含有カルボン酸誘導体
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
AU784377B2 (en) * 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis

Also Published As

Publication number Publication date
EP1274456A2 (de) 2003-01-15
HK1053053B (zh) 2005-06-10
EP1274456B1 (de) 2004-12-29
DE60108094T2 (de) 2005-12-15
WO2001080894A2 (en) 2001-11-01
WO2001080894A3 (en) 2002-07-25
ATE285794T1 (de) 2005-01-15
CA2407021A1 (en) 2001-11-01
JP2003531180A (ja) 2003-10-21
AU5548801A (en) 2001-11-07
US20030114482A1 (en) 2003-06-19
AU2006233216A1 (en) 2006-11-16
AU2001255488B2 (en) 2006-07-27
HK1053053A1 (en) 2003-10-10

Similar Documents

Publication Publication Date Title
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE60120372D1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
DE60220887D1 (de) Agonisten von beta-adrenorezeptoren
EA200300845A1 (ru) Модифицированные антитела и способы применения
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE434437T1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee